Eli Lilly’s ongoing technology evaluation agreement with Peptron remains strictly limited to non-binding joint research on applying the SmartDepot microsphere-based sustained-release platform to peptide candidates, including GLP-1 agents for obesity and expanded CNS indications. This setup grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing—factors reinforced by Lilly’s separate exclusive deal with Camurus’ FluidCrystal platform and the lack of any binding technology transfer announcement as the October 7 deadline approaches. While recent patent grants and in-vivo studies show continued technical progress, the market-implied 94.5% probability for no deal reflects the evaluation-only structure and absence of commercialization signals. A surprise last-minute binding agreement remains possible but would require rapid reversal of established timelines.